Journals / Turkish Journal of Hematology / 2012 / Cilt: 29 - Sayı: 4

Non-Hodgkin lenfomalı çinli hastalarda serum p53 proteini konsantrasyonunun prognostik önemi

The prognostic significance of the serum p53 protein concentration in chinese patients with non-Hodgkin lymphoma

Pages
376–384
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Following conventional chemotherapy, the complete/partial remission (CR/PR) rate was significantly higher and overall survival (OS) was significantly longer in the patients with early-stage (stage I-II) lymphoma, normal karyotype, and a low serum p53 protein concentration than in those with advanced-stage (stage III-IV) lymphoma, cytogenetic abnormalities, and a high serum p53 protein concentration (≥0.35 U/mL).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the prognostic significance of cytogenetic abnormalities, staging, patient factors, and the serum p53 protein concentration in Chinese non-Hodgkin lymphoma (NHL) patients.
📊
Key Findings & Data:Material and Methods: The study included 43 patients with NHL that were identified between August 2003 and December 2008.
💡
Conclusion & Impact:Results: Following conventional chemotherapy, the complete/partial remission (CR/PR) rate was significantly higher and overall survival (OS) was significantly longer in the patients with early-stage (stage I-II) lymphoma, normal karyotype, and a low serum p53 protein concentration than in those with advanced-stage (stage III-IV) lymphoma, cytogenetic abnormalities, and a high serum p53 protein concentration (≥0.35 U/mL).
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the prognostic significance of cytogenetic abnormalities, staging, patient factors, and the serum p53 protein concentration in Chinese non-Hodgkin lymphoma (NHL) patients. Material and Methods: The study included 43 patients with NHL that were identified between August 2003 and December 2008. Patient clinical characteristics patients were determined based on morphological, immunohistochemical, and cytogenetic analysis, and the serum p53 protein concentration was measured quantitatively. Results: Following conventional chemotherapy, the complete/partial remission (CR/PR) rate was significantly higher and overall survival (OS) was significantly longer in the patients with early-stage (stage I-II) lymphoma, normal karyotype, and a low serum p53 protein concentration than in those with advanced-stage (stage III-IV) lymphoma, cytogenetic abnormalities, and a high serum p53 protein concentration (&#8805;0.35 U/mL). Bone marrow infiltration was also a predictor of poor response and OS. There weren&#8217;t any significant differences in disease remission between the male and female patients, older and younger patients (aged <70 years vs. &#8805;70 years), or B-cell lymphoma and T-cell lymphoma patients. Conclusion: Staging is an effective means of assessing the severity of NHL. Cytogenetic examination can provide useful information for diagnosis, staging, and prognostication. The serum p53 protein level may be a potential prognostic marker in patients with NHL.

Özet

Amaç: Çinli non-Hodgkin lenfoma (NHL) hastalarında sitogenetik anormallikler, evrelendirme, hasta faktörleri ve serum p53 proteini konsantrasyonunun prognostik önemini araştırmak. Gereç ve Yöntemler: Çalışmaya Ağustos 2003 ile Aralık 2008 arasında tanımlanan 43 NHL hastası dahil edildi. Hasta klinik özellikleri morfolojik, immünohistokimyasal ve sitogenetik analiz temelinde belirlendi ve serum p53 proteini konsantrasyonu kantitatif olarak ölçüldü. Bulgular: Geleneksel kemoterapi sonrasında erken dönem (evre I-II) lenfoma, normal karyotip ve düşük serum p53 protein konsantrasyonu olan hastalarda tam/kısmi remisyon oranı ileri dönem (evre III-IV) lenfoma, sitogenetik bozukluklar ve yüksek serum p53 proteini konsantrasyonu (≥0,35 U/mL) olan hastalara göreönemli ölçüde daha yüksek ve genel sağkalım önemli ölçüde daha uzundu. Kemik iliği infiltrasyonu da kötü cevap ve genel sağkalımın bir prediktörüydü. Erkek ve kadın hastalar, yaşlı ve genç hastalar (<70 yaş ve ≥70 yaş) veya B-hücreli lenfoma ve T-hücreli lenfoma hastaları arasında hastalık remisyonu açısından önemli farklar yoktu. Sonuç: Evrelendirme NHL şiddetini değerlendirmenin etkin bir yoludur. Sitogenetik inceleme tanı, evrelendirme ve prognoz belirleme için faydalı bilgiler sunabilir. Serum p53 proteini düzeyi NHL hastalarında olası bir prognostik işaret olabilir.

🔖

Cite This Article

ZHOU, M., CEN, L., CHEN, T., XIAO, R., YANG, J., GIANG, N., ZHANG, Y. (2012). Non-Hodgkin lenfomalı çinli hastalarda serum p53 proteini konsantrasyonunun prognostik önemi. Turkish Journal of Hematology, Cilt: 29 - Sayı: 4, 376–384. https://ajindex.com/articles/412652

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Fisher RI. Overview of non-Hodgkin’s lymphoma: Biology, staging, and treatment. Semin Oncol 2003; 30:3-9
  2. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003; 362:139-146
  3. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Wardiman JW, eds. World Health Organization Classification of tumours of Haematopoietic and Lymphoid Tissues,Lyon, France:IARC Press 2001
  4. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res 2009; 127:1-4
  5. Sukpanichnant S, Sonakul D, Piankijagum A, Wanachiwanawin W, Veerakul G, Mahasandana C, Tanphaichitr VS, Suvatte V. Malignant lymphoma in Thailand. Changes in the frequency of malignant lymphoma determined from a histopathologic and immunophenotypic analysis of 425 cases at Siriraj Hospital. Cancer 1998; 83:1197-1204
  6. Donner LR. Cytogenetics of lymphoma: A brief review of its theoretical and practical significance. Cancer Genet Cytogenet 1997;94:20-26
  7. Ong ST, Le Beau MM. Chromosomal abnormalities and molecular genetics of non-Hodgkin’s lymphoma. Semin Oncol 1998;25: 447–460
  8. Poirel HA, Cairo MS, Heerema NA, Swansbury J, Aupérin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphaël M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: Results of the FAB/LMB 96 international study. Leukemia 2009; 23:323- 331
  9. Johnson NA, Al-Tourah A, Brown CJ, Connors JM, Gascoyne RD, Horsman DE. Pognostic Significance of Secondary Cytogenetic Alterations in Follicular Lymphomas. Genes Chromosomes Cancer 2008; 47(12):1038-1048
  10. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, Haites NE. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128–2132
  11. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725–734
  12. Winrow CJ, Pankratz DG, Vibat CR, Bowen TJ, Callahan MA, Warren AJ, Hilbush BS, Wynshaw-Boris A, Hasel KW, Weaver Z, Lockhart DJ, Barlow C. Aberrant recombination involving the granzyme locus occurs in Atm-/- T-cell lymphomas. Hum Mol Genet 2005; 14:2671-2684
  13. Sanchez E, Chacon I, Plaza MM, Muñoz E, Cruz MA, Martinez B, Lopez L, Martinez-